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the experimental type I error. When modifying scientific hypoth-
eses during a trial, one is essentially testing the global hypothesis
that at least one of the treatment regimens tested affects at least
one of the proposed clinical outcomes in at least one of the iden-
tified target populations. This could lead to severe problems both
in estimating efficacy and defining the actual indication. Also the
idea of ‘seamless’ phase II/III trials was discussed. Although such
designs might seem advantageous, phase II studies must not be
slighted in dose finding and other aspects. In some cases, regula-
tors may already be requiring too little work in phase II. Further-
more, many phase II/III trials are not truly adaptive; rather, they
are designed as phase III trials in settings where adequate infor-
mation on biological activity is lacking.
It is mainly the early phases of drug development, being inher-
ently more exploratory than confirmatory, which could benefit
from flexibility in trial design. Adaptive designs are not often
used, although requests for scientific advice about them is rather
frequent.
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This presentation reflected a personal opinion about the role of
surrogates as clinical end-points. According to the Biomarkers
Definitions Working Group, a surrogate is ‘a biomarker that is
intended to substitute for a clinical end-point and is expected
to predict clinical benefit (or harm or lack of clinical benefit) based
on epidemiologic, therapeutic, pathophysiologic or other scien-
tific evidence’.1 Although overall survival is the gold standard
recognised by both the European Medicines Agency (EMEA) and
the US Food and Drug Administration (FDA) as a basis for condi-
tional (EMEA) or accelerated (FDA) approval of new anticancer
agents, surrogate end-points are often considered to be reason-
ably likely to predict clinical benefit.
WHAT IS REQUIRED FOR DRUG REGISTRATION OR APPROVAL?:
The European Union’s legal requirements for approval of a new
agent were highlighted. First, it must demonstrate a positive ben-
efit–risk ratio. Second, whenever possible, the agent should be
compared in a randomised, controlled clinical trial to a placebo
or an established treatment (as appropriate). Measures must be
taken to minimise bias and uncertainty. Authorisation will be
refused, however, if the agent’s efficacy is not substantiated or
is lacking, or if the agent is shown to be harmful.
The FDA’s International Conference on Harmonisation gener-
ated two general considerations for clinical trials that are relevant
to the use of surrogates as end-points.2,3 Confirmatory (phase III)
trials should demonstrate clinical benefit, and the primary end-
point should provide the most clinically relevant and convincing
evidence of effect based on a valid and reliable measure indicative
of treatment benefit.
Clinical end-points for approval or registration of anticancer
agents include overall, disease-free or progression-free survival
(PFS).8 PFS has generally relied on imaging or the onset or worsen-
ing of disease-related symptoms. Response, if the effect is dra-
matic, may also be a basis for approval. Tumour response is
most often based on imaging results or Response Evaluation Cri-
teria in Solid Tumours (RECIST),5 a set of standard parameters
used to document and report tumour response. Protection against
toxicity and reduction in the risk of disease can also be acceptable
bases for approval or registration. In general, patient benefit is
difficult to use as a clinical end-point because of the lack of reli-
able, reproducible instruments for measuring such factors as pal-
liation or improvement of symptoms. Quality-of-life assessments
are not presently considered as a basis for approval.
The EMEA’s experience shows that it has been quite flexible in
accepting end-points other than overall survival and PFS for
approval. Indeed, almost half of approvals are based on response
rate (Table 1). Response rate is only used as a basis for approval
when the anticancer agent demonstrates ‘dramatic activity’ in
the EMEA guideline or in situations where no established alterna-
tives exist and the prognosis is relatively homogeneous (e.g.
imatinib mesylate, Glivec) for chronic myeloid leukaemia after
failure of interferon). Overall, response rate has been an end-
point in 22 trials (47%), PFS in 16 (34%), and overall survival in 9
(19%). The experience of the FDAwith end-points other than over-
all survival was also discussed. Table 2 shows the proportions of
Table 1 – EMEA experience with various end-points used
in drug-registration trials
Indication N = 47 End-points
Hematologic 13 (28%) PFS, RR
Breast 13 (28%) OS, PFS, RR
Sarcoma 5 (11%) RR
Lung cancer 5 (11%) OS
Colorectal 3 (6%) OS, RR
Brain cancer 3 (6%) OS, PFS, RR
Ovarian 3 (6%) PFS, RR
Head and neck 1 (2%) RR
Prostate 1 (2%) OS
PFS, progression-free survival; RR, response rate; OS, overall
survival.
Table 2 – FDA experience with various end-points used
in clinical trials in support of accelerated or regular
approval
Accelerated (%) Regular (%)
Response rate 93 53
Time to progression 7 20
Symptom benefit 0 12
Other 7 32
Columns do not total 100% due to multiple end-points.
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clinical studies that relied upon various end-points to support
accelerated or regular approval.
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